Hsbc Holdings PLC Makes New $5.25 Million Investment in Bruker Corporation $BRKR

Key Points

• HSBC Holdings acquired 88,647 Bruker shares worth approximately $5.25 million in the second quarter, while institutional investors collectively own 79.52% of the company.
• Analysts maintain a broadly positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $56.64; several firms recently raised their targets to between $60 and $70.
• Bruker exceeded quarterly EPS expectations, reporting $0.49 versus the $0.38 consensus estimate, although revenue of $838.5 million fell short of forecasts. The company also declared a quarterly dividend of $0.05 per share.

Hsbc Holdings PLC bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 88,647 shares of the medical research company's stock, valued at approximately $5,252,000. Hsbc Holdings PLC owned approximately 0.06% of Bruker as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the fourth quarter valued at $26,000. Allworth Financial LP raised its holdings in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Essential Partners LLC purchased a new stake in Bruker in the first quarter worth about $36,000. Global Retirement Partners LLC purchased a new stake in Bruker in the second quarter worth about $38,000. Finally, Parallel Advisors LLC grew its holdings in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company's stock worth $41,000 after acquiring an additional 479 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on BRKR shares. Leerink Partners boosted their price target on shares of Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a report on Tuesday, July 7th. Guggenheim lifted their price objective on shares of Bruker from $50.00 to $70.00 and gave the company a "buy" rating in a report on Monday, June 29th. TD Cowen reissued a "hold" rating on shares of Bruker in a research note on Wednesday, July 15th. Barclays upped their target price on Bruker from $53.00 to $60.00 and gave the stock an "overweight" rating in a report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. increased their target price on Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a research report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Bruker currently has an average rating of "Moderate Buy" and a consensus price target of $56.64.

Bruker Trading Down 3.7%

NASDAQ BRKR opened at $57.08 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm has a market cap of $8.70 billion, a PE ratio of -81.54, a price-to-earnings-growth ratio of 1.81 and a beta of 1.28. The company has a 50 day moving average price of $58.77 and a 200 day moving average price of $48.00. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $65.30.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the company posted $0.32 EPS. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio (DPR) is presently -28.57%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source